Altimmune Reports Q4 Revenue of $26,000
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy ALT?
Reports Q4 revenue $26,000 vs. $5,000 last year. "In pemvidutide, we have a unique and differentiated compound with the potential to address critical unmet needs of patients with serious liver diseases such as MASH. We are committed to taking the necessary steps to realize its value for all of our stakeholders and have significantly progressed our efforts to strengthen our financial and operational foundation," said Jerry Durso, President and Chief Executive Officer of Altimmune. "We remain focused on ensuring that we have the means and the capabilities to successfully execute Phase 3 development in MASH and capture the significant opportunities ahead of us. We have a number of important inflection points in 2026, most notably the upcoming initiation of our Phase 3 trial of pemvidutide in MASH, for which we are actively finalizing the study plan. Finally, we look forward to the topline data from our RECLAIM Phase 2 trial of pemvidutide in AUD, which we expect to release in the third quarter."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALT
Wall Street analysts forecast ALT stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.860
Low
12.00
Averages
16.00
High
20.00
Current: 3.860
Low
12.00
Averages
16.00
High
20.00
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Altimmune Reports Q4 2025 Earnings and Phase III Trial Plans
- Clinical Trial Progress: Altimmune plans to initiate a global Phase III MASH trial in 2026, enrolling approximately 1,800 patients to primarily assess the efficacy of pemvidutide at 1.8 mg and 2.4 mg doses, aiming to address significant unmet needs in liver disease.
- Improved Financial Position: As of year-end 2025, Altimmune reported total cash of $274 million, with a pro forma cash position expected to extend into 2028 following January's fundraising, thereby supporting the advancement of clinical programs.
- R&D Expense Changes: R&D expenses for Q4 2025 were $18.4 million, a decrease from $19.8 million in the same period of 2024, indicating a strategic adjustment in resource allocation by the company.
- Positive Market Response: Market research indicated that over 70% of physicians expressed a high likelihood of prescribing pemvidutide, with projected usage rates of 43% and 51% among F2 and F3 patients, respectively, suggesting strong potential acceptance and competitiveness in the market.
See More
Altimmune's Financial Status and Trial Progress
- Strong Cash Position: As of the end of February, Altimmune reported cash and cash equivalents of $340 million, which is deemed sufficient to sustain operations into 2028, ensuring stability for upcoming research and trial activities over the next few years.
- FDA Approval on Trial Design: Altimmune has agreed with the U.S. FDA on the design of the upcoming MASH trial, which is expected to evaluate multiple doses of pemvidutide, supporting potential accelerated approval, indicating the company's strategic positioning in drug development.
- Disappointing Financial Results: The company reported a net loss of $0.27 per share for Q4, which, while an improvement from $0.33 in the same period of 2024, exceeded Wall Street's estimate of $0.24, leading to a 9% drop in stock price on Thursday, reflecting market concerns over financial performance.
- Shifting Market Sentiment: Despite the stock decline, retail sentiment on Stocktwits shifted from 'bearish' to 'bullish', with message volume increasing from 'low' to 'normal', indicating investor optimism regarding potential partnerships or buyout opportunities for the company.
See More
Altimmune Announces Late-Stage Trial Plans for Pemvidutide
- Late-Stage Trial Launch: Altimmune plans to initiate a late-stage trial for metabolic dysfunction-associated steatohepatitis (MASH) in Q4 2025, aiming to evaluate multiple doses of pemvidutide over 52 weeks with biopsy-based endpoints to support potential accelerated approval.
- FDA Breakthrough Therapy Designation: Earlier this year, the company received FDA's Breakthrough Therapy Designation for pemvidutide as a treatment for MASH, which boosted Altimmune's stock price, reflecting positive market sentiment towards its R&D progress.
- Disappointing Financial Results: Despite the positive R&D news, Altimmune reported a GAAP loss per share of $0.27 in Q4, missing analysts' expectations by $0.03, with R&D expenses reaching $18.4 million, exceeding the Bloomberg consensus of $17.4 million, leading to a ~7% drop in stock price.
- Future Outlook: CEO Jerry Durso highlighted that 2026 will be a pivotal year, particularly with the upcoming initiation of the MASH Phase 3 trial, and despite current financial setbacks, the company is actively finalizing the study plan to drive product development.
See More
Altimmune (ALT) Q4 2025 Earnings Call Transcript
See More
Altimmune Q4 Earnings Report Analysis
- Earnings Performance: Altimmune reported a Q4 GAAP EPS of -$0.27, missing expectations by $0.03, indicating challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $30,000, beating expectations by $30,000 and significantly increasing from $5,000 in the same quarter last year, suggesting a rebound in product demand that could lay the groundwork for future performance improvements.
- Cash Position: As of December 31, 2025, Altimmune's cash, cash equivalents, and short-term investments totaled $274 million, reflecting the company's financial stability, which supports future R&D and operational needs.
- Financing Activity: The company strengthened its balance sheet through a $75 million registered direct offering in January 2026, providing essential funding for upcoming clinical trials and market expansion efforts.
See More
Altimmune Scheduled to Announce Q4 Earnings on March 5
- Earnings Announcement: Altimmune is set to announce its Q4 earnings on March 5 before market open, with a consensus EPS estimate of -$0.24, indicating ongoing challenges in profitability.
- Earnings Estimate Revisions: Over the past three months, Altimmune's EPS estimates have seen two upward revisions with no downward adjustments, reflecting cautious optimism from analysts that could influence investor sentiment.
- Funding Activity: Altimmune recently priced a $75 million direct offering, which will provide crucial funding to support its R&D projects, particularly in advancing the clinical trials for Pemvidutide.
- FDA Breakthrough Designation: Altimmune has gained FDA breakthrough designation for its MASH therapy, a development that not only enhances the company's market position but may also expedite the product's path to market, increasing future revenue potential.
See More
Altimmune Reports Q4 2025 Earnings and Phase III Trial Plans
- Clinical Trial Progress: Altimmune plans to initiate a global Phase III MASH trial in 2026, enrolling approximately 1,800 patients to primarily assess the efficacy of pemvidutide at 1.8 mg and 2.4 mg doses, aiming to address significant unmet needs in liver disease.
- Improved Financial Position: As of year-end 2025, Altimmune reported total cash of $274 million, with a pro forma cash position expected to extend into 2028 following January's fundraising, thereby supporting the advancement of clinical programs.
- R&D Expense Changes: R&D expenses for Q4 2025 were $18.4 million, a decrease from $19.8 million in the same period of 2024, indicating a strategic adjustment in resource allocation by the company.
- Positive Market Response: Market research indicated that over 70% of physicians expressed a high likelihood of prescribing pemvidutide, with projected usage rates of 43% and 51% among F2 and F3 patients, respectively, suggesting strong potential acceptance and competitiveness in the market.
See More
Altimmune's Financial Status and Trial Progress
- Strong Cash Position: As of the end of February, Altimmune reported cash and cash equivalents of $340 million, which is deemed sufficient to sustain operations into 2028, ensuring stability for upcoming research and trial activities over the next few years.
- FDA Approval on Trial Design: Altimmune has agreed with the U.S. FDA on the design of the upcoming MASH trial, which is expected to evaluate multiple doses of pemvidutide, supporting potential accelerated approval, indicating the company's strategic positioning in drug development.
- Disappointing Financial Results: The company reported a net loss of $0.27 per share for Q4, which, while an improvement from $0.33 in the same period of 2024, exceeded Wall Street's estimate of $0.24, leading to a 9% drop in stock price on Thursday, reflecting market concerns over financial performance.
- Shifting Market Sentiment: Despite the stock decline, retail sentiment on Stocktwits shifted from 'bearish' to 'bullish', with message volume increasing from 'low' to 'normal', indicating investor optimism regarding potential partnerships or buyout opportunities for the company.
See More
Altimmune Announces Late-Stage Trial Plans for Pemvidutide
- Late-Stage Trial Launch: Altimmune plans to initiate a late-stage trial for metabolic dysfunction-associated steatohepatitis (MASH) in Q4 2025, aiming to evaluate multiple doses of pemvidutide over 52 weeks with biopsy-based endpoints to support potential accelerated approval.
- FDA Breakthrough Therapy Designation: Earlier this year, the company received FDA's Breakthrough Therapy Designation for pemvidutide as a treatment for MASH, which boosted Altimmune's stock price, reflecting positive market sentiment towards its R&D progress.
- Disappointing Financial Results: Despite the positive R&D news, Altimmune reported a GAAP loss per share of $0.27 in Q4, missing analysts' expectations by $0.03, with R&D expenses reaching $18.4 million, exceeding the Bloomberg consensus of $17.4 million, leading to a ~7% drop in stock price.
- Future Outlook: CEO Jerry Durso highlighted that 2026 will be a pivotal year, particularly with the upcoming initiation of the MASH Phase 3 trial, and despite current financial setbacks, the company is actively finalizing the study plan to drive product development.
See More
Altimmune (ALT) Q4 2025 Earnings Call Transcript
See More
Altimmune Q4 Earnings Report Analysis
- Earnings Performance: Altimmune reported a Q4 GAAP EPS of -$0.27, missing expectations by $0.03, indicating challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $30,000, beating expectations by $30,000 and significantly increasing from $5,000 in the same quarter last year, suggesting a rebound in product demand that could lay the groundwork for future performance improvements.
- Cash Position: As of December 31, 2025, Altimmune's cash, cash equivalents, and short-term investments totaled $274 million, reflecting the company's financial stability, which supports future R&D and operational needs.
- Financing Activity: The company strengthened its balance sheet through a $75 million registered direct offering in January 2026, providing essential funding for upcoming clinical trials and market expansion efforts.
See More
Altimmune Scheduled to Announce Q4 Earnings on March 5
- Earnings Announcement: Altimmune is set to announce its Q4 earnings on March 5 before market open, with a consensus EPS estimate of -$0.24, indicating ongoing challenges in profitability.
- Earnings Estimate Revisions: Over the past three months, Altimmune's EPS estimates have seen two upward revisions with no downward adjustments, reflecting cautious optimism from analysts that could influence investor sentiment.
- Funding Activity: Altimmune recently priced a $75 million direct offering, which will provide crucial funding to support its R&D projects, particularly in advancing the clinical trials for Pemvidutide.
- FDA Breakthrough Designation: Altimmune has gained FDA breakthrough designation for its MASH therapy, a development that not only enhances the company's market position but may also expedite the product's path to market, increasing future revenue potential.
See More
